These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 3888381)

  • 21. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
    Fang J; Sawa T; Maeda H
    Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
    Sato H; Hori K; Sugiyama K; Tanda S; Sato Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1191-200. PubMed ID: 10945016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
    Sreerama L; Sládek NE
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induced hypertension chemotherapy of cancer patients by selective enhancement of drug delivery to tumor tissue with angiotensin II.
    Sato H; Sato K; Sato Y; Asamura M; Kanamaru R; Sugiyama Z; Kitahara T; Mimata Y; Wakui A; Suzuki M; Hori K; Abe I; Saito S; Sato H
    Sci Rep Res Inst Tohoku Univ Med; 1981 Dec; 28(1-4):32-44. PubMed ID: 7345574
    [No Abstract]   [Full Text] [Related]  

  • 26. Nanoparticles for delivery of chemotherapeutic agents to tumors.
    Vijayaraghavalu S; Raghavan D; Labhasetwar V
    Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Targeting of anticancer chemotherapy utilizing the characteristic nature of the neovasculature of solid tumors].
    Konno T; Ohtsuka N; Yamasaki K; Mizutani J; Miyauchi Y; Maeda H; Matsumura Y
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1448-55. PubMed ID: 2425743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE; Kollander R; Sreerama L; Kiang DT
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study on angiotensin-induced hypertension chemotherapy (IHC)].
    Sato H; Hoshi M; Wakui A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1439-47. PubMed ID: 3729461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.
    Ghattass K; Assah R; El-Sabban M; Gali-Muhtasib H
    Curr Cancer Drug Targets; 2013 Jul; 13(6):670-85. PubMed ID: 23687923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Changes in tumor transvascular pressure difference associated with tumor growth: implications for angiotensin-induced hypertension chemotherapy].
    Hori K; Suzuki M; Abe I; Saito S
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1630-7. PubMed ID: 4026332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy.
    Stylianopoulos T; Munn LL; Jain RK
    Trends Cancer; 2018 Apr; 4(4):258-259. PubMed ID: 29606306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental chemotherapy and concepts related to the cell cycle.
    Tannock IF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1986 Feb; 49(2):335-55. PubMed ID: 3510996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Restriction of drug transport by the tumor environment.
    Nandigama R; Upcin B; Aktas BH; Ergün S; Henke E
    Histochem Cell Biol; 2018 Dec; 150(6):631-648. PubMed ID: 30361778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.
    Escargueil AE; Prado S; Dezaire A; Clairambault J; Larsen AK; Soares DG
    Curr Pharm Des; 2016; 22(44):6625-6644. PubMed ID: 27587198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure.
    Jain RK; Baxter LT
    Cancer Res; 1988 Dec; 48(24 Pt 1):7022-32. PubMed ID: 3191477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multistep, effective drug distribution within solid tumors.
    Shemi A; Khvalevsky EZ; Gabai RM; Domb A; Barenholz Y
    Oncotarget; 2015 Nov; 6(37):39564-77. PubMed ID: 26416413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.
    Norton L
    Oncologist; 2005; 10(6):370-81. PubMed ID: 15967831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.